Pipeline
EM Imaging radiopharmaceuticals portfolio
Edinburgh Molecular Imaging has a portfolio of agents designed to improve detection and treatment of Cancer. All Agents progressed to date have been found to be safe, specific, sensitive and selective.
PET Imaging
![Pipeline-non-conf-PET-May-2021-1](https://emimaging.com/wp-content/uploads/2019/12/Pipeline-non-conf-PET-Dec-2021.png)
Therapy
![Pipeline-non-conf-May-2021](https://emimaging.com/wp-content/uploads/2019/12/Pipeline-non-conf-May-2021.png)
Indications to be disclosed at a later stage.
![](https://emimaging.com/wp-content/uploads/2019/10/EMI0103_Logo_RGB.png)
About Us
EM Imaging was founded in 2014 to develop a versatile and disease focused approach to optical tracer and therapeutic compounds development.
Edinburgh Molecular Imaging Ltd.
Nine
9 Little France Road
Edinburgh BioQuarter (Gate 3)
Edinburgh EH16 4UX
United Kingdom
Recent News
Edinburgh Molecular Imaging – 2021